Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 178 entries
View as:

Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193037 Org: User:
Start: 02/28/01 End: 11/30/09 Due: 11/30/10

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

Phase: N/A Priority: Normal
NCT ID: NCT00805961 Org: User:
Start: 01/31/09 End: 05/31/13 Due: 05/31/14

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

Phase: N/A Priority: Normal
NCT ID: NCT01611857 Org: User:
Start: 07/31/12 End: 08/31/15 Due: 08/31/16

Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00633594 Org: User:
Start: 06/30/08 End: 11/30/16 Due: 11/30/17

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00613145 Org: User:
Start: 02/29/08 End: 05/31/10 Due: 05/31/11

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04402138 Org: User:
Start: 08/07/20 End: 04/05/24 Due: 04/05/25

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00390611 Org: User:
Start: 10/31/06 End: 04/30/14 Due: 04/30/15

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT00960297 Org: User:
Start: 08/31/09 End: 05/31/13 Due: 05/31/14

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01154335 Org: User:
Start: 07/31/10 End: 05/31/13 Due: 05/31/14

Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor

Phase: N/A Priority: Normal
NCT ID: NCT01404650 Org: User:
Start: 12/31/11 End: 02/28/15 Due: 02/28/16

Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193453 Org: User:
Start: 07/31/05 End: 12/31/09 Due: 12/31/10

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01769508 Org: User:
Start: 02/28/13 End: 02/28/15 Due: 02/28/16

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01121939 Org: User:
Start: 05/31/10 End: 08/31/15 Due: 08/31/16

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01027598 Org: User:
Start: 01/31/10 End: 06/30/14 Due: 06/30/15

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT05972135 Org: User:
Start: 10/23/23 End: 03/31/26 Due: 03/31/27

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02168101 Org: User:
Start: 09/30/14 End: 02/01/19 Due: 02/01/20

Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00392821 Org: User:
Start: 12/31/06 End: 10/31/13 Due: 10/31/14

Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193115 Org: User:
Start: 03/31/04 End: 01/31/09 Due: 01/31/10

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02300935 Org: User:
Start: 12/31/15 End: 01/20/16 Due: 01/20/17

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193245 Org: User:
Start: 11/30/00 End: 01/31/09 Due: 01/31/10

Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01829113 Org: User:
Start: 07/31/13 End: 04/19/17 Due: 04/19/18

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02317991 Org: User:
Start: 05/05/15 End: 05/21/21 Due: 05/21/22

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00193050 Org: User:
Start: 11/30/01 End: 03/31/09 Due: 03/31/10

LBH589 and Gemcitabine in the Treatment of Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00550199 Org: User:
Start: 11/30/07 End: 02/28/10 Due: 02/28/11

Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib

Phase: N/A Priority: Normal
NCT ID: NCT01487265 Org: User:
Start: 03/31/14 End: 12/11/17 Due: 12/11/18